PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
CMB International Global Markets  Equity Research  Company Update
Tigermed (300347 CH)
Business stabilizing from late September
Tigermed reported 3Q23 revenue of RMB1940mn up 71% YoY (vs 33%
YoY (vs 29% YoY in 1H23) 3Q23 revenue accounted for 249% of our 2023
full-year estimate in line with its historical average while attributable recurring
average of 27% If excluding COVID vaccine revenue 3Q23 revenue would
grow by 18% YoY (vs 27% YoY in 1H23) Management indicated a policy
headwind impacting patient enrolments in 3Q23 which has already largely
resumed normal by late Sep Gross profit margin (GPM) in 3Q23 continuously
rose to 412% improving by 10ppt QoQ and 02ppt YoY According to
management GPM would be 417% if excluding COVID vaccine revenue
which declined 13ppt YoY The adj gross margin dilution was mainly due to
the impact from policy headwinds margin pressure from lab business and the
strong recovery of low-margin SMO services Additionally new orders
(excluding pass-through fees) signed in the quarter achieved positive growth
amid the harsh business environment Tigermeds operating cash flows in 9M23
was RMB673mn down 185% YoY
 Globalization to serve as a long-term driver Tigermed acquired a
Croatia-based clinical CRO Marti Farm in Jan 2023 further enhancing its
service capability in Europe Althrough the Company adjusted its personnel
in Europe to reflect the post-COVID demand changes Europe still plays a
critical role for patient enrolments in MRCTs as well as for biosimilar
projects In the US Tigermed doubled its local clinical operation team to
more than 110 staff in 1H23 In the Europe and US market Tigermed
intention of incorporating China in their MRCTs (especially CGT projects)
and Chinese clients going to overseas markets Management expected the
growth of the US and EU business to outpace that of Tigermed as a whole
Besides Southeast Asia and Latin America market with large population
bases continue to remain as strategic end markets for Chinese pharma
 ADC and obesity to trigger additional clinical demands Although the
global biotech market has saw an initial inflection point in terms of financing
management of Tigermed pointed out the continuously decreasing risk
tolerance of clients leading to the longer waiting time from request-for-
proposals (RFPs) to contract signing However management indicated that
international market such as ADC and obesity drugs will bring additional
clinical demands to clinical CROs Specifically Tigermed has already
observed a growing interest from client on obesity drugs
 Maintain BUY We revised our TP from RMB9441 to RMB8031 based on
a 10-year DCF model (WACC 115% terminal growth 30%) to factor in
revenue to grow 73% 249% 260% YoY and attributable recurring net
(Previous TP
UpDownside
Jill WU CFA
Benchen HUANG CFA
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source FactSet
Shareholding Structure
Source HKEx
Source FactSet
12-mth Price Performance
Source FactSet
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Adjusted net profit (RMB mn)
EPS (Adjusted) (RMB)
Consensus EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Earnings revision
Recurring EPS (RMB)
Source Company data CMBIGM estimates
Figure 2 CMBIGM estimates vs consensus
Recurring EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
Figure 3 Risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
PV of terminal value (RMB mn)
Total PV (RMB mn)
Net debt (RMB mn)
Equity value (RMB mn)
Minority (RMB mn)
 of shares (mn)
Price per share (RMB per share) 8031
Source CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
RD expense
Gainloss on financial assets at FVTPL
Investment gainloss
Pre-tax profit
YE 31 Dec (RMB mn)
Cash  equivalents
Non-current assets
Investment in JVs  assos
Financial assets at FVTPL
Other non-current assets
Short-term borrowings
Other current liabilities
Non-current liabilities
Long-term borrowings
Obligations under finance leases
Other non-current liabilities
Total shareholders equity
Total equity and liabilities
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
Profit before taxation
Depreciation  amortization
Change in working capital
Net cash from operations
Acquisition of subsidiaries investments
Net proceeds from disposal of short-term
Net cash from investing
Proceeds from share issues
Net cash from financing
Cash at the beginning of the year
Cash at the end of the year
Adj net profit
Adj net profit margin
Return on equity (ROE)
GEARINGLIQUIDITYACTIVITIES
Net debt to equity (x)
Current ratio (x)
Receivable turnover days
Inventory turnover days
Payable turnover days
PE (diluted)
Div yield (%)
Source Company data CMBIGM estimates Note The calculation of net cash includes financial assets
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve as
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned
subsidiary of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the
report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM
or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIGM nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the inform ation contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIGM may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with
and CMBIGM will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIGM
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified
as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules
intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is
intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing to
effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined
in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its
respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations
Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities
and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law
Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report